The prognostic effect of the peak level of serum creatine kinase (CK) and aspartate transaminase (AST), estimated daily for 3-5 days after acute myocardial infarction, was studied in 560 patients who survived the first day in hospital. In a subgroup of 54 patients, peak enzyme levels correlated well with the cumulated CK release (r = 0.90 with peak CK, r = 0.74 with peak AST), thus reflecting the extent of myocardial necrosis. Total mortality within a year after infarction was not significantly different in the lower three quintiles of peak serum enzyme level, but increased from 15.5% to 27.9% (p < 0.001) when peak CK level exceeded eight times the upper limit of normal (8 X N) and from 13.1% to 34.8% (p < 0.001) when peak AST level exceeded five times the upper limit of normal (5 X N). The effect of high enzyme levels was more marked in patients with a prior history of myocardial infarction; mortality increased from 14.7% for first infarctions to 18.2% for recurrent infarctions, with peak CK < 8 X N, and from 27.0% for first infarctions to 38.0% for recurrent infarctions with peak CK > 8 X N. Early mortality was more significantly affected (p < 0.0001) than late mortality (p < 0.05). In hospital survivors, late deaths from cardiac decompensation were three times (p < 0.05) more frequent in the high enzyme group as in the low enzyme group, but the number of sudden deaths was unaffected. These findings have important implications for studies of reduction of myocardial infarct size.
SUMMARY The prognostic effect of the peak level of serum creatine kinase (CK) and aspartate transaminase (AST), estimated daily for 3-5 days after acute myocardial infarction, was studied in 560 patients who survived the first day in hospital. In a subgroup of 54 patients, peak enzyme levels correlated well with the cumulated CK release (r = 0.90 with peak CK, r = 0.74 with peak AST), thus reflecting the extent of myocardial necrosis. Total mortality within a year after infarction was not significantly different in the lower three quintiles of peak serum enzyme level, but increased from 15.5% to 27.9% (p < 0.001) when peak CK level exceeded eight times the upper limit of normal (8 X N) and from 13.1% to 34.8% (p < 0.001) when peak AST level exceeded five times the upper limit of normal (5 X N). The effect of high enzyme levels was more marked in patients with a prior history of myocardial infarction; mortality increased from 14.7% for first infarctions to 18.2% for recurrent infarctions, with peak CK < 8 X N, and from 27.0% for first infarctions to 38.0% for recurrent infarctions with peak CK > 8 X N. Early mortality was more significantly affected (p < 0.0001) than late mortality (p < 0.05). In hospital survivors, late deaths from cardiac decompensation were three times (p < 0.05) more frequent in the high enzyme group as in the low enzyme group, but the number of sudden deaths was unaffected. These findings have important implications for studies of reduction of myocardial infarct size.
THE STUDIES OF Maroko and Braunwald' and others2 indicating that appropriate interventions can limit myocardial necrosis in experimental animals, have suggested that limitation of myocardial damage will improve prognosis in patients with myocardial infarction. 3 4 This approach to the treatment of myocardial infarction assumes that prognosis and infarct size are closely related.5 This assumption has not been closely examined in the past because methods of estimating infarct size have not been available. With the recent development of methods of estimating the total cardiac enzyme release from serum enzyme estimations,6 a relationship between this indicator of the extent of myocardial necrosis and short-term prognosis has been demonstrated in a small group of patients.7 However, the serial blood sampling, biochemical analysis and computation required to measure total cardiac enzyme release is expensive and time-consuming and not suitable for large scale studies. In this study, routine clinical and biochemical data were examined to obtain the index which best reflected total enzyme release and its effect on prognosis in a group of patients in the acute phase and in the year after recovery from acute myocardial infarction.
Patients and Methods

Patient Admission and Follow-up
All 580 patients fulfilling the World Health Organization (WHO) criteria for definite myocardial infarctions admitted to the coronary care unit, in the 3-year period from January 1, 1973 to January 1, 1976 were studied in the acute phase and followed up for 1 year. Twenty patients with typical clinical or electrocardiographic features of myocardial infarction died on the first hospital day; these patients were excluded, leaving 560 patients for analysis. Clinical data was recorded in a standardized format suitable for computer analysis. Past history, physical examination, blood pressure (sphygmomanometer), chest x-ray and electrocardiographic changes were recorded upon admission to the hospital; past history of myocardial infarction was recorded if there was a history of typical pain, corroborated by hospital or doctor's reports of typical electrocardiographic and enzyme abnormalities, occurring at least 1 month before the episode requiring admission. Patients were examined daily throughout their hospital course, reviewed by postal questionnaire at 3 months and 12 months after admission to hospital. The date and circumstances of death were recorded from published death notices and confirmed by the visit of a social worker to the family. At 12 months those patients whose death had not been recorded and who had not replied to the postal questionnaire were contacted by telephone or home visit. Follow-up was 100%.
Estimation of Total Enzyme Release in a Subgroup of 54 Patients
In a subgroup of 54 consecutive patients fulfilling WHO criteria8 for definite acute myocardial infarc- tion whose chest pain had occurred within 12 hours of hospital admission, and who had no evidence of skeletal muscle injury or other noncardiac source of creatine kinase (CK) the total CK release6'9 was calculated. A polyethylene catheter (gauge 22 Intracath Bardic) was inserted into the antecubital vein and advanced to the superior vena cava. For 24-48 hours from the time of admission to hospital, 4-ml samples of blood were taken at 2-hour intervals. The specimens were frozen at 4°C and CK concentration was measured within 24 hours by Technicon autoanalyzer using the Siegel Cohen technique.'0 Total CK release was calculated from the formula devised by Shell et al. 6 Results were expressed as total units CK released per ml; separate estimations were performed using 1) enzyme disappearance rate (kd) as 0.06/hr, the mean value obtained by Sobel et al. in a group of patients;7 2) kd calculated individually by the method described by Norris et al." and 3) kd calculated individually from the midpoint on the downslope on the best fit log-normal curve derived from the 2-hour samples. 12 
Correlation of Total Enzyme Release With Routine Data
In the above subgroup of 54 patients, the total enzyme release was correlated with routine clinical and biochemical data to establish the most accurate indirect indicator of total enzyme release.
Coronary Prognostic Index
Clinical and electrocardiographic measurements at the time of hospital admission were used to calculate a coronary prognostic index by the method of Norris et al. 1 
Daily Serum Enzyme Estimations
Upon admission and subsequently at 9 a.m. for the first 5 days of the hospitalization, 9-ml samples of blood were taken by venepuncture for estimation of serum CK and serum asparatate transaminase (AST) (glutamic oxaloacetic transaminase). The peak of the daily enzyme level was taken as the highest enzyme level recorded on the first 5 days of hospitalization. Results are expressed in IU/1, and where appropriate, converted to multiples of the upper limit of normal (= XN), which for CK was 130 IU/I and for AST was 40 IU/l. Body temperature was taken orally at 6-hour intervals and expressed in degrees centrigrade. The peak temperature for a 24-hour period was recorded. The peak of the daily temperatures was taken as the highest recording in the first 5 days. The area under the curve was calculated by summation of the°C by which the peak daily temperature exceeded 37°C in the first 5 days. In the subgroup of 54 patients the correlation between the total CK release and clinical estimation of severity was poor: Temperature chart analysis showed that neither the peak body temperature nor the sum of the daily temperatures for the first 5 days correlated with cumulated ck (r = 0.09 and 0.32, respectively). The systolic blood pressure on admission did not correlate (r = -0.30), nor did the coronary prognostic index (r = 0.07).
In contrast, routine daily serum enzyme estimations correlated well with total CK release estimated with a mean kd of 0.06/hr. Both the peak and the sum of the first 5 days of CK estimations were closely correlated (r = 0.90, r = 0.91) ( fig. 1 ). When the total CK release was estimated with individual kd estimates, the correlation with peak CK remained close, r = 0.85. The peak and the sum of the daily AST estimations also correlated well (r = 0.74, r = 0.86, respectively) ( fig. 1 ). Total 
1-Year Mortality in 560 Patients
The clear relationship between peak serum enzyme levels and the total (i.e., hospital and post-hospital) mortality in the year after infarction is shown in figure 2. When the 560 patients who survived the first day were allocated to five groups of 112 according to peak serum enzyme levels, mortality in the lower three quintiles was similar, 12-17% in each of the three groups. No significant differences in mortality could be discerned among patients with peak CK levels as great as 1090 IU/l (approximately 8 times the upper limit of normal, 8XN), or peak AST levels as great as 195 IU/I (approximately 5XN). Mortality increased from 15.5% to 27.9% when the lower three quintiles were compared with the upper two quintiles of peak CK level (p < 0.001), and from 13.1% to 34.8% when the lower three and upper two quintiles (above & below 195 IU/1, 5XN) of peak AST were compared (p < 0.001). There was a further increase (p < 0.01) in mortality between the fourth and fifth quintiles of peak level of both enzymes. We noted marked differences in mortality when patients were divided into upper and lower halves of peak enzyme levels (table 1). First vs Recurrent Infarctions Four hundred three patients with first infarction had a mortality of 25.5%, and 157 patients with recurrent infarction had a mortality of 20.3% (p < 0.05). Within each of these groups, mortality was higher when peak enzyme levels were high ( fig. 3 ). The mortality ratio for patients with peak levels above rather than below 8XN was 1.8 (27.0% vs 14.7%; p < 0.01) for first infarctions, and 2.1 (38% vs 18.2%, p < 0.01) for patients with recurrent infarction. Mortality increased stepwise from 14.7% for first infarction to 18.2% with recurrent infarctions when peak CK was less than 8 X N, 27% for first infarctions to 38% for recurrent infarctions when peak CK was greater than 8XN ( fig. 3 ). 
Early vs Late Mortality
The increased mortality in patients with high peak enzyme levels was more marked in the early postinfarction period than after recovery. The in-hospital mortality is shown on the shaded portion of the bar graphs in figure 2. There were no significant differences in the lower three quintiles, but the higher hospital mortality at higher peak enzyme levels is obvious. In table 1, the patients in the lower three and upper two quintiles (CK below and above 1090 IU/1, AST below and above 169 IU/l) are compared. In each case, the differences in hospital mortality between the high-and low-enzyme level groups were highly significant (p < 0.001). The differences in posthospital mortality were less striking. While there were clearcut differences when peak AST levels were compared, comparison of peak CK levels showed only marginal differences.
The survival curves ( fig. 4 ), confirm the high early mortality in patients with high peak CK levels, with a less significant impact in later weeks; survival was similar in the lower three quintiles, worse in the fourth quintiles and markedly worse in the highest quintile (CK > 1711 IU/1). The lower part of figure 4 compares the lower three quintiles with the upper two. From the fourth week on, the divergence between the two groups was barely perceptible and statistical analysis of survival at various intervals shows that the highly significant differences in the first three weeks were not sustained from the 4th through 52nd week (table 2). The differences in survival between patients in each AST quintile were more evenly sustained throughout the year.
Mode of Late Death
In the year after hospital discharge, patients who had had high peak CK levels in hospital had an increased rate of death from cardiac decompensation,
but not of sudden cardiac death (table 3) . The death rate from cardiac decompensation in the year after hospital discharge was three times greater (4.1% vs 1.3%, p < 0.05) when peak CK had exceeded 1090 IU/I (about 8XN), while the sudden death rate did not differ (7.2% vs 9.4%). When patients were reallocated into two halves around the median value of 780 IU/l (6xN), it was found that only one death from cardiac decompensation occurred in the lower half. Similarly, deaths from cardiac decompensation were significantly more frequent in the upper AST levels. Thus, all the differences in post-hospital deaths were due to differences in deaths from cardiac decompensation, and the sudden death rate was uninfluenced by peak enzyme level in the acute episode ( fig. 5 ).
Discussion
The basis for our conclusions about the extent of myocardial necrosis was the formula for cumulation of CK release devised and validated in canine myocardial infarction by Shell et al. 6 The technique has been modified for human application by Sobel et al.,7 incorporating facts known of the human myocardial content and kinetics of CK. This approach could be criticized because it is not possible to estimate accurately the total grams of necrotic myocardium because of the variability of the "constants" in the formula (the fraction of the enzyme destroyed in its passage from the heart cannot be readily calculated; the effects of hemodynamic changes on enzyme distribution volume are not known; the use of an average value for the fractional disappearance rate introduces inaccuracies9' 12). However, many of the potentially variable "constants" from the calculations can be eliminated, and the results expressed in units of enzyme released per liter of plasma rather than extrapolating to "gram equivalents" of infarct size.9 When groups of patients are being compared, as in the present study, the perturbations in the constants in the formula and the absolute units used to express the extent of myocardial necrosis become even less relevant. The validity of the technique as an estimate of the extent of myocardial necrosis has been confirmed by excellent correlation with infarct size measured postmortem in patients who have died of myocardial infarction. '4 Estimation of the extent of myocardial necrosis by calculation of CK release, however, is not practical for routine use. The collection and assay of a large number of blood samples is uneconomical and entails some patient inconvenience. We established that the peak of the daily serum enzyme estimations correlated well with the calculated total CK release. When results are expressed as total CK release per ml, complete correlation with the peak results would be expected if sampling were frequent enough and an average kd were used. But even when the sampling interval was 24 hours and the kd was individualized by two different methods, the r value between peak level and cumulated CK release was still 0.85 in the subgroup of patients in which they were compared. Therefore, it seemed justifiable to use the peak of the daily CK 230 23 10.0 9 3.9 4 1.7 Difference NS <0.05 NS Note the increased incidence of death from cardiac decompensation in patients with high levels of peak enzymes, but no effect on sudden cardiac death. less close for peak AST than for peak CK; its validity as an indicator of the extent of myocardial necrosis would be correspondingly less. In 560 patients followed for a year after infarction, there was a clear-cut relationship between peak enzyme levels and overall mortality, consistent with the concept that the extent of myocardial necrosis is a major determinant of prognosis. AST levels contributed to prognosis throughout the year, reflecting the dual origin of AST from myocardium and hepatic necrosis secondary to hemodynamic dysfunction.1"-18 On the other hand, the effect of mortality of the peak CK level, predominantly reflecting the extent of myocardial necrosis, decreased after the first few weeks. The differences in late mortality between those with enzymatic evidence of small vs large infarctions were only marginally significant; undoubtedly, other prognostic factors, such as the extent of coronary disease,'9, 20 the extent of prior myocardial dysfunction21 and possibly the electrical stability of the myocar-dium22 were important in the' postinfarction period.
The surprisingly high sudden death rate in patients with small enzyme rises may reflect the failure of some patients to "complete" an infarction, resulting in a limited release of myocardial enzymes, leaving an area of unstable myocardium as a source of subsequent lethal arrhythmias. This interpretation is consistent CIRCULATION 118 with observations on persons who have been resuscitated from ventricular fibrillation in whom evidence of myocardial necrosis at the time of the arrhythmia appeared to reduce the risk of a subsequent recurrence.23 Nevertheless, the deleterious effect of cumulative myocardial destruction was clearly demonstrated in this study by the progressive increase in mortality from 15% for a small new infarction, to 18% for a small recurrent infarction, to 27% for a large new infarction, and as much as 38% for a large recurrent infarction.
This study confirms that preservation of myocardium from ischemic necrosis should be pursued. The major impact of a clinically applicable method of limiting infarct size would be on the early phase of mortality in myocardial infarction; in the year after recovery, deaths due to cardiac decompensation might be reduced; other interventions would be necessary to influence the risk of late sudden death.
